Navigation Links
Anti-Tumour Drug More Potent With Light-Directed Delivery
Date:8/19/2009

OSLO, August 19 /PRNewswire/ --

- PCI Biotech's Light-Activated Drug Delivery System Combines With Tumour-Targeting Drugs to Halt Tumour Growth at Low Doses

The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech's light-activated delivery system, a new study shows.

Researchers say this dual therapy approach could be employed to increase the effect and lower the side effects of anti-cancer drugs in humans.

The researchers tested the approach on mice with human non-pigmented melanoma skin cancer grafts, using a drug consisting of a very potent toxin fused to an antibody fragment that recognizes a protein commonly found on the cancer cells, but not on normal cells. This allowed them to target the tumour cells specifically. Whilst drug therapy alone did not significantly slow growth of the tumours, using PCI to enhance the delivery process substantially improved the results.

Thus, in mice treated with both PCI and the tumour-targeting drug, half of the animals did not reach the defined end point for tumour growth, even by the end of the study (after 110 days). By contrast, all the mice receiving the drug alone had reached the endpoint after just 40 days, which was not significantly different from what was seen in untreated control animals. There were also no adverse effects on the mice, indicating that PCI technology can allow the use of drug doses so low that unwanted side effects in humans could be substantially reduced.

The study, by researchers at the Norwegian Radium Hospital in Oslo, Norway, and the M.D. Anderson Cancer Center in Houston, Texas, is published in the journal PLoS ONE.

Lead author of the study, Dr. Pal K. Selbo, comments: "In this study we have used an advanced biotechnological drug that consists of a protein toxin fused to a cancer-targeting moiety. The combination of the tumour targeting by the antibody and the light-directed drug delivery achieved by PCI gives extraordinarily specific therapy, effectively combining two different principles for specifically targeting the tumour cells. The increased delivery efficiency offered by the PCI technology makes it possible to achieve very good therapeutic effects with drug doses substantially lower than what is necessary without the help of PCI. The study demonstrates the excellent effect of the PCI technology with a very promising class of anticancer drugs, and could pave the way for the efficient and safe use of such drugs in humans."

Per Walday, CEO of PCI Biotech, adds: "This study further demonstrates the potential of the PCI technology in combination with important new classes of therapies. These results clearly demonstrate that PCI as a modality may greatly improve the efficacy of cell-targeted therapeutic agents. Our main priority going forward is to move the PCI technology into the clinic, to prove its safety and efficacy in man."

For more information visit: http://www.pcibiotech.com


'/>"/>
SOURCE PCI Biotech
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
5. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
6. SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
9. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading custom ... Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The ... for its annual event, which will run from 3:00 p.m. - 8:30 p.m. ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... expansion to their comprehensive training and support program, Sonalink™ remote monitoring. The inaugural ... procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical ... Alzheimer’s disease, announced today it has been selected to present at the Cavendish Global ... Palm Beach, Florida. The purpose of the Forum is to help family offices ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):